ARCHIVES

FDA, NCI, CMS Announce Biomarker Initiative; First Project To Validate FDG-PET As Predictor Of Tumor Response In Non-Hodgkin’s Lymphoma.

This article is from The Cancer Letter archive.

Vol. 32 No. 06 | February 17, 2006

Download PDF Visit The Full Archive

Related Articles

Capitol Hill: Bills Seeks Coverage for Treatment Of cancers Found in CDC Screening

April 2, 1999

FDA Designates Zometa For Priority Review.

November 30, 2001

Hammer Blast GAO Report As ”Gobblygook”

June 12, 1987

Letters: Alternatives Needs Scrutiny, Investigator Open-Mindedness

December 3, 1993

Gene Expression Analyses Can Guide MDS Treatments

December 30, 2011

A letter about FDA oncology consolidation reopens debate among cancer groups; FDA asks groups not to send letters, invites discussion.

June 4, 2004